BluePath Capital Management’s Axcelis ACLS Stock Holding History

BluePath Capital Management’s Portfolio ACLS Stock Details ACLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,496	Closed	-$244K	–	107
2023 Q3	$244K	Buy	+1,496	New	+$263K	0.22%	81

Other funds holding ACLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BluePath Capital Management's ACLS Position: Q4 2023 in Review

BluePath Capital Management sold out of Axcelis (ACLS) in Q4 2023, closing a stake of 1,496 shares — an estimated $244K sold.

BluePath Capital Management first reported a position in ACLS in Q3 2023 and held it in 1 quarter. The position peaked at $244K in Q3 2023. 421 funds tracked by Wall St. Rank hold ACLS as of Q4 2023.

BluePath Capital Management reported no remaining Axcelis position as of Q4 2023 after selling out during the quarter.
BluePath Capital Management sold 1,496 Axcelis shares in Q4 2023, an estimated $244K.
BluePath Capital Management first reported a position in Axcelis in Q3 2023 and held it in 1 quarter.
BluePath Capital Management's Axcelis position peaked at $244K in Q3 2023.
421 funds tracked by Wall St. Rank held Axcelis as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.